JP2022515330A5 - - Google Patents
Info
- Publication number
- JP2022515330A5 JP2022515330A5 JP2021531831A JP2021531831A JP2022515330A5 JP 2022515330 A5 JP2022515330 A5 JP 2022515330A5 JP 2021531831 A JP2021531831 A JP 2021531831A JP 2021531831 A JP2021531831 A JP 2021531831A JP 2022515330 A5 JP2022515330 A5 JP 2022515330A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- acid sequence
- tmmp
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782167P | 2018-12-19 | 2018-12-19 | |
| US62/782,167 | 2018-12-19 | ||
| US201962814684P | 2019-03-06 | 2019-03-06 | |
| US62/814,684 | 2019-03-06 | ||
| PCT/US2019/067575 WO2020132297A1 (en) | 2018-12-19 | 2019-12-19 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515330A JP2022515330A (ja) | 2022-02-18 |
| JP2022515330A5 true JP2022515330A5 (enExample) | 2022-12-26 |
| JP7549579B2 JP7549579B2 (ja) | 2024-09-11 |
Family
ID=71100921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531831A Active JP7549579B2 (ja) | 2018-12-19 | 2019-12-19 | 多量体ｔ細胞調節ポリペプチド及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220112252A1 (enExample) |
| EP (2) | EP3897701B1 (enExample) |
| JP (1) | JP7549579B2 (enExample) |
| KR (1) | KR20210104673A (enExample) |
| CN (1) | CN113286609B (enExample) |
| AU (1) | AU2019404285B2 (enExample) |
| BR (1) | BR112021011814A2 (enExample) |
| CA (1) | CA3113100A1 (enExample) |
| DK (1) | DK3897701T3 (enExample) |
| ES (1) | ES3052836T3 (enExample) |
| IL (1) | IL281505B2 (enExample) |
| MX (1) | MX2021007287A (enExample) |
| MY (1) | MY206813A (enExample) |
| PH (1) | PH12021500027A1 (enExample) |
| SG (1) | SG11202103863UA (enExample) |
| SI (1) | SI3897701T1 (enExample) |
| TW (1) | TWI856047B (enExample) |
| WO (1) | WO2020132297A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201808552XA (en) * | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2021230638A1 (en) * | 2020-05-12 | 2021-11-18 | Lg Chem, Ltd. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| WO2022015880A2 (en) * | 2020-07-14 | 2022-01-20 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| WO2022099157A1 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| EP4308143A4 (en) * | 2021-03-19 | 2025-06-04 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| CN117222421A (zh) * | 2021-03-19 | 2023-12-12 | Cue生物制药股份有限公司 | T细胞调节多肽和其使用方法 |
| WO2023081718A1 (en) * | 2021-11-04 | 2023-05-11 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN114805538B (zh) * | 2022-05-20 | 2023-06-09 | 广州智瓴生物医药有限公司 | 一种增强til功效的培养方法 |
| WO2026125765A1 (en) | 2024-12-13 | 2026-06-18 | Immunoscape Pte. Ltd. | Combination therapy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US9205144B2 (en) | 2011-06-03 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Identification of conserved peptide blocks in homologous polypeptides |
| LT2945647T (lt) * | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai |
| JP6652932B2 (ja) * | 2014-06-18 | 2020-02-26 | アルバート アインシュタイン カレッジ オブ メディシン | ｓｙｎＴａｃポリペプチド及びその使用 |
| ES2774380T3 (es) * | 2014-08-29 | 2020-07-20 | Hoffmann La Roche | Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| HUE059694T2 (hu) * | 2015-11-20 | 2022-12-28 | Memorial Sloan Kettering Cancer Center | Készítmény rák kezelésére |
| SG11201808552XA (en) * | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN110325205B (zh) * | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) * | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| US11725210B2 (en) * | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| MX2020002596A (es) * | 2017-09-07 | 2020-07-20 | Cue Biopharma Inc | Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. |
| WO2019051127A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2020132366A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| WO2020132365A2 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| EP4030897A4 (en) * | 2019-09-20 | 2023-10-18 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| US20230117521A1 (en) * | 2020-03-25 | 2023-04-20 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| IL296209A (en) * | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| EP4308143A4 (en) * | 2021-03-19 | 2025-06-04 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
-
2019
- 2019-12-18 TW TW108146526A patent/TWI856047B/zh active
- 2019-12-19 MX MX2021007287A patent/MX2021007287A/es unknown
- 2019-12-19 EP EP19900784.0A patent/EP3897701B1/en active Active
- 2019-12-19 SI SI201930988T patent/SI3897701T1/sl unknown
- 2019-12-19 WO PCT/US2019/067575 patent/WO2020132297A1/en not_active Ceased
- 2019-12-19 SG SG11202103863UA patent/SG11202103863UA/en unknown
- 2019-12-19 PH PH1/2021/500027A patent/PH12021500027A1/en unknown
- 2019-12-19 AU AU2019404285A patent/AU2019404285B2/en active Active
- 2019-12-19 DK DK19900784.0T patent/DK3897701T3/da active
- 2019-12-19 JP JP2021531831A patent/JP7549579B2/ja active Active
- 2019-12-19 BR BR112021011814A patent/BR112021011814A2/pt unknown
- 2019-12-19 CN CN201980080657.4A patent/CN113286609B/zh active Active
- 2019-12-19 CA CA3113100A patent/CA3113100A1/en active Pending
- 2019-12-19 KR KR1020217015556A patent/KR20210104673A/ko not_active Ceased
- 2019-12-19 ES ES19900784T patent/ES3052836T3/es active Active
- 2019-12-19 MY MYPI2021001671A patent/MY206813A/en unknown
- 2019-12-19 EP EP25193554.0A patent/EP4650365A3/en active Pending
-
2021
- 2021-03-15 IL IL281505A patent/IL281505B2/en unknown
- 2021-05-21 US US17/326,837 patent/US20220112252A1/en not_active Abandoned
-
2024
- 2024-07-10 US US18/768,830 patent/US20250074960A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536581A5 (enExample) | ||
| JP2019512222A5 (enExample) | ||
| JP7270001B2 (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 | |
| JP7573075B2 (ja) | 変異型ｐ５３を認識するｔ細胞受容体 | |
| JP2021500855A5 (enExample) | ||
| JP7385566B2 (ja) | 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 | |
| Kelly et al. | A new human HLA class II-related locus, DM | |
| IL272085B2 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2020511949A5 (enExample) | ||
| JP7635165B2 (ja) | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 | |
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| JP2022515331A5 (enExample) | ||
| JP2021191265A5 (enExample) | ||
| JP2023526723A5 (enExample) | ||
| WO2020082130A1 (en) | T-cell receptors and uses thereof | |
| JP2017519491A5 (enExample) | ||
| JP2015535816A5 (enExample) | ||
| JP2010527919A5 (enExample) | ||
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| JP7735285B2 (ja) | Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 | |
| JP2022522405A5 (enExample) | ||
| JP7742354B2 (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| JP2023541366A5 (enExample) | ||
| CN114901684A (zh) | 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子 |